Dan’l
:
** Shares of biotech Chimerix CMRX rise 171.68% to $2.35 after the bell ** Company plans to submit an application seeking FDA's accelerated approval in the U.S. for its drug dordaviprone as a treatment for a type of glioma before year-end ** Adds it will be ready for a U.S. launch as early as Q3 2025 ** CMRX is seeking approval of dordaviprone as a treatment for recurrent H3 K27M-mutant diffuse glioma, a type of tumor that forms in the brain ** Up to last close, stock down ~10% YTD (Reporting bv Sriparna Rov
Chimerix Stock Forum
No comment yet